 - Women of child-bearing potential must agree to use adequate contraception barrier method of birth control, or abstinence; hormonal contraception is not allowed for the duration of study participation, and for at least 2 weeks after treatment with dabrafenib or for 6 months after dabrafenib in combination with trametinib; should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately 